Vergoeding 2017-2021 voor ATC-subgroep G04BD : Middelen bij urge-incontinentie
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| G04BD02 Flavoxaat (Urispas ®) | 108.360 | 93.555 | 84.011 | 85.235 | 79.679 |
| G04BD04 Oxybutynine (Dridase ®) | 569.320 | 611.250 | 1.529.400 | 1.698.400 | 2.444.700 |
| G04BD07 Tolterodine (Detrusitol ®) | 459.780 | 534.660 | 682.920 | 705.780 | 645.980 |
| G04BD08 Solifenacine (Vesicare ®) | 12.888.500 | 12.467.500 | 11.713.500 | 6.749.000 | 4.284.700 |
| G04BD10 Darifenacine (Emselex ®) | 1.490.000 | 1.323.600 | 1.271.800 | 1.218.000 | 1.168.600 |
| G04BD11 Fesoterodine (Toviaz ®) | 1.373.500 | 1.273.800 | 1.274.500 | 1.245.500 | 1.215.400 |
| G04BD12 Mirabegron (Betmiga ®) | 4.352.300 | 5.114.300 | 5.701.200 | 6.077.200 | 6.549.800 |
| Totaal | 21.241.760 | 21.418.665 | 22.257.331 | 17.779.115 | 16.388.859 |